drugset / Trial / NCT00355628

Clinical Study of KW-2246 in Patients With Cancer Pain

NCT00355628

Phase 2 Completed 40 enrolled Kyowa Kirin, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study is a Phase II open-label study to investigate the recommended conversion ratio (oral morphine dose to KW-2246) when switching oral morphine or oxycodone to KW-2246 in cancer patients.

Timeline

Start
2006-07
Primary completion
2007-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified

Indications